Chosa Oncology AB
Research Chosa Oncology AB (CHOSA.ST) with Bullrun company financials, valuation charts, model signals, and historical stock context.
Key Metrics
- TickerCHOSA.ST
- ExchangeST
- CountrySweden
- SectorHealthcare
- IndustryBiotechnology
- CurrencySEK
- Financial periodQ2 2026
- RevenueSEK 0
- Net income-SEK 2.63M
- Free cash flow-SEK 3.08M
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | SEK 0 | -SEK 1.00M | -SEK 8.88M | n/a | -0.01 | SEK 1.79M | n/a | SEK 16.54M |
About Chosa Oncology AB
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.
Related stock research
Other Healthcare stocks
Frequently asked questions
What does Chosa Oncology AB do?
Chosa Oncology AB, together with its subsidiaries, engages in developing and commercializing medicines for the treatment of cancer in Sweden and USA. It provides Platin-DRP, a multigene mRNA-based algorithm that predicts a patient's response to platinum-based chemotherapy; and LiPlaCis, a liposomal formulation of cisplatin, enabling delivery of chemotherapy agent directly to tumor sites. The company was formerly known as Chosa ApS. Chosa Oncology AB was incorporated in 2015 and is based in Malmö, Sweden.